QURE Company Profile and Key Details

Q: Who are the executives of QURE?

Mr. Matthew Craig KapustaChief Executive Officer & Executive DirectorMs. Erin BoyerChief People & Culture OfficeMs. Maria E. CantorChief Corporation Affairs OfficerMr. Pierre CalozChief Operating OfficerDr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance OfficerMr. David CervenyChief Legal Officer, Gen. Counsel & Sec.Dr. Ricardo Dolmetsch Ph.D.Pres & Chief Scientific OfficerDr. Alexander E. Kuta Ph.D.Chief Regulatory OfficerDr. Tamara Tugal Ph.D., MBABus. Devel. DirectorMr. Richard Porter Ph.D.Chief Bus. OfficerMr. Christian KlemtChief Financial Officer, Principal Financial Officer & GM of Amsterdam SiteProf. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany

NASDAQ : QURE

uniQure NV

$45.10

-0.9-1.96%

Open: 3:33 PM

59.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

uniQure N.V. (QURE) stock declined over -1.96%, trading at $45.10 on NASDAQ, down from the previous close of $46.00. The stock opened at $45.68, fluctuating between $44.86 and $45.82 in the recent session.

Stock Snapshot

Prev. Close

3.13B

Market Cap

44.86

Day Low

-11.25

P/E Ratio

-4.01

EPS (TTM)

-3.2

Cash Flow per Share

45.68

Open

69.37M

Number of Shares

45.82

Day High

89.33%

Free Float in %

4.34

Book Value

568.29K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 09, 2026	45.71	46.98	45.37	46.00	1.3M
Sep 08, 2026	43.38	46.25	43.05	45.68	1.35M
Sep 04, 2026	44.91	45.16	43.90	44.50	991.34K
Sep 03, 2026	45.50	46.03	44.03	44.86	1.3M
Sep 02, 2026	50.72	50.97	45.25	46.23	2.48M
Sep 01, 2026	48.63	48.85	47.29	47.86	748.79K
Aug 31, 2026	48.23	48.86	47.59	48.68	1.64M
Aug 28, 2026	49.51	49.51	48.29	48.72	843.42K
Aug 27, 2026	50.83	51.03	49.51	49.56	778.35K
Aug 26, 2026	50.90	51.20	50.05	50.95	898.99K
Aug 25, 2026	48.00	51.72	47.92	51.05	2.19M
Aug 24, 2026	48.00	48.04	46.34	47.46	920.82K
Aug 21, 2026	48.91	49.85	48.19	48.37	673.48K
Aug 20, 2026	48.00	49.64	47.08	48.89	1.2M
Aug 19, 2026	48.00	49.02	46.93	48.76	1.28M
Aug 18, 2026	47.42	48.20	46.87	47.38	500.69K
Aug 17, 2026	48.08	48.50	46.87	47.97	838.41K
Aug 14, 2026	47.06	48.70	46.31	48.62	956.38K
Aug 13, 2026	44.96	47.27	44.22	47.06	1.12M
Aug 12, 2026	45.11	46.15	44.93	45.13	736.44K

Contact Details

Amsterdam, NH 1105 BP

Netherlands

https://www.uniqure.com 312 024 06000

About Company

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Peers

ARGX

-4.76-0.47%

argenx SE$1,002.31 REGN

-2.66-0.33%

Regeneron Pharmaceuticals, Inc.$807.65 MDGL

12.5+2.34%

Madrigal Pharmaceuticals, Inc.$546.66 VRTX

-7.78-1.47%

Vertex Pharmaceuticals Incorporated$521.12 UTHR

8.85+1.78%

United Therapeutics Corporation$506.82 ONC

-0.48-0.14%

BeOne Medicines AG$351.00 KRYS

-3.17-0.90%

Krystal Biotech, Inc.$348.09 PRAX

-7.18-2.04%

Praxis Precision Medicines, Inc.$345.30 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-0.78-0.27%

Ligand Pharmaceuticals Incorporated$288.05

Frequently Asked Questions

What is the current uniQure N.V. (QURE) stock price?

uniQure N.V. (NASDAQ: QURE) stock price is $45.10 in the last trading session. During the trading session, QURE stock reached the peak price of $45.82 while $44.86 was the lowest point it dropped to. The percentage change in QURE stock occurred in the recent session was -1.96% while the dollar amount for the price change in QURE stock was - $0.90.

QURE's industry and sector of operation?

The NASDAQ listed QURE is part of Biotechnology industry that operates in the broader Healthcare sector. uniQure N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of QURE?

Mr. Matthew Craig Kapusta
Chief Executive Officer & Executive Director
Ms. Erin Boyer
Chief People & Culture Office
Ms. Maria E. Cantor
Chief Corporation Affairs Officer
Mr. Pierre Caloz
Chief Operating Officer
Dr. Jeannette Potts J.D., Ph.D.
Chief Legal & Compliance Officer
Mr. David Cerveny
Chief Legal Officer, Gen. Counsel & Sec.
Dr. Ricardo Dolmetsch Ph.D.
Pres & Chief Scientific Officer
Dr. Alexander E. Kuta Ph.D.
Chief Regulatory Officer
Dr. Tamara Tugal Ph.D., MBA
Bus. Devel. Director
Mr. Richard Porter Ph.D.
Chief Bus. Officer
Mr. Christian Klemt
Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
Prof. Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

How QURE did perform over past 52-week?

QURE's closing price is 426.92% higher than its 52-week low of $8.73 where as its distance from 52-week high of $71.50 is -35.66%.

How many employees does QURE have?

Number of QURE employees currently stands at 221.

Link for QURE official website?

Official Website of QURE is: https://www.uniqure.com

How do I contact QURE?

QURE could be contacted at phone 312 024 06000 and can also be accessed through its website. QURE operates from Paasheuvelweg 25, Amsterdam, NH 1105 BP, Netherlands.

How many shares of QURE are traded daily?

QURE stock volume for the day was 568.29K shares. The average number of QURE shares traded daily for last 3 months was 1.86M.

What is the market cap of QURE currently?

The market value of QURE currently stands at $3.13B with its latest stock price at $45.10 and 69.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	221
Beta	0.94
Sales or Revenue	$15.84M
5Y Sales Change%	0.05%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	221
Beta	0.94
Sales or Revenue	$15.84M
5Y Sales Change%	0.05%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

QURE Company Profile and Key Details

uniQure NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways